#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Industry Analysis
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Average visit duration of Tumblr.com is 10 mins and 25 secs.
Text
Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market 2018-2025 - Industry Applications, Market Share, Segmentation, Company Share
Non-Hodgkin’s Lymphoma (NHL), has been expected to reach a new landscape in the forecast period due to the constant innovation and improvements on finding a viable drug to battle this disease. Due to the inability of major pharmaceuticals companies having a viable solution to it, the cost of treatment is very high and hence, the market is expected to soar higher in the forecast period of 2018-2025.
Request for Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-non-hodgkins-lymphoma-and-chronic-lymphoma-treatment-market
Definition: Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market
Non-Hodgkin’s Lymphoma is a type of cancer that attacks the lymphoma tic cells that are present in our immune system and fights off infection and diseases. It is commonly found in both adults and children, and these type of cancerous cells can be found anywhere throughout the body, as the lymphoma tic cells are spread throughout the body.
Market Drivers
·Increasing cases of cancer, and chronic diseases are also one of the major drivers of this market
·Improved healthcare services available in the major regions of the world would also be one of the major drivers
Market Restraints
·Rising cost treatment and drugs still yet to be approved by the specific authorities would prove to be a major road-block in its progress
·Chemotherapy’s side effects are also set to halt any major growth in the sector
Market Segmentation: Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market
·By treatment, all of the segments related to various treatments available in the market are set to witness worldwide growth due to the increasing cancer cases and no particular viable proven drug in the market. Global lymphoma treatment is set to witness healthy growth in all treatment segments.
·By geography, North America has been dominating the Non-Hodgkin’s Lymphoma treatment market due to its frequency of cancer cases, and it is set to continue that trend for the foreseeable future, followed by the APAC region of the world where it has developed better healthcare services and infrastructure.
Inquiry Before Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-multiple-sclerosis-treatment-market
Key Developments in the Market:
·In August 2017,Gilead Sciences, Inc. and Kite Pharma, Inc. entered into a definitive agreement in August,2017 where the drug developed by Kite Pharma, Inc. currently under review by the US FDA, and is set to be one of the first drugs to be marketed for Non-Hodgkin’s Lymphoma
·In November 2017,US FDA approved a drug called Calquence by AstraZeneca, plc and will hit the market for an aggressive form of Non-Hodgkin’s Lymphoma in adults
Competitive Analysis: Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market
Extensive R&D currently being conducted throughout the major pharmaceutical firms finding a treatment for Non-Hodgkin’s Lymphoma, but due to the high amount of R&D cost, it is proving to be a major hurdle in trying to find a viable solution and treatment.
More information for Report @ https://databridgemarketresearch.com/reports/global-non-hodgkins-lymphoma-and-chronic-lymphoma-treatment-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email:
#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Industry Analysis#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Research Report#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Research Report#Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market#Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Research Report
0 notes
Text
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030
Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market
Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.
Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.
To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Key Market Insights
Over 755 CAR-T cell therapies are currently approved / under development
Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.
Currently, the focus is on developing product candidates to treat various types of cancers
Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.
Extensive efforts are underway to improve CAR constructs
Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.
China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.
Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).
Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).
The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
Key Questions Answered
§ Who are the leading industry and non-industry players in this market?
§ What are the prevalent R&D trends in CAR-T cell therapies domain?
§ What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
§ What are the challenges faced by stakeholders in this industry?
§ Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What kind of contract manufacturing support is available for CAR-T cell therapies?
§ What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:
§ Disease indication
§ Non-Hodgkin lymphoma
§ Multiple myeloma
§ Chronic lymphocytic leukemia
§ Acute lymphoblastic leukemia
§ Follicular lymphoma
§ Mantle cell lymphoma
§ Hepatocellular carcinoma
§ Colorectal cancer
§ Target antigens
§ CD19
§ BCMA
§ CD19, CD22
§ GPC3
§ EGFR
§ Key Geographical Regions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Rest of the World
The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
§ Tim Oldham (Chief Executive Officer, Cell Therapies)
§ Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
§ Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
§ Miguel Forte (Chief Operating Officer, TxCell)
§ Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
§ Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
§ Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
§ Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
§ Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
§ Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
§ Autolus
§ bluebird bio
§ CARsgen Therapeutics
§ Celgene (A Bristol Myers Squibb Company)
§ Cellectis
§ Cellular Biomedicine Group
§ Innovative Cellular Therapeutics
§ Iovance Biotherapeutics
§ Kite Pharma (A Gilead Sciences Company)
§ Kuur Therapeutics
§ Noile-Immune Biotech
§ Novartis
§ Shanghai Genechem
§ Sinobioway Cell Therapy
§ Takara Bio
§ Ziopharm Oncology
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email [email protected]
You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
2. mRNA Therapeutics and Vaccines Market, 2020-2030
3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
0 notes
Text
Biosimilars Market Demand, Size, Share, Scope & Forecast to 2030
The Global Biosimilar Market is expected to be valued at USD 159.02 Billion by 2030 from USD 15.6 Billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2030.
Medicines known as biologics or biological products are created using living organisms through extremely intricate production procedures. They must be handled and administered under strict supervision. The term "biologics" refers to a broad range of goods, including vaccines, therapeutic proteins, monoclonal antibodies, and cell and gene therapies. Biologics are used to prevent, treat, or cure a number of illnesses, such as cancer, diabetes, cystic fibrosis, chronic kidney disease, and autoimmune disorders. Biologics are at the cutting edge of scientific and biological research and may be able to treat a variety of illnesses for which there are no other effective treatments.
A biotherapeutic product that is extremely similar to a reference biologic medication is referred to as a biosimilar, also known as a follow-on biologic. It has a complicated molecular structure and is made from living things or cells. Manufacturers rely on regulatory authority authorisation to launch the production of biosimilars when the patent on a biologic medication expires. A biological medication must be demonstrated to be identical in terms of quality, safety, and efficacy in order to be labelled as a biosimilar. Biosimilars are more expensive than generic medications because their production needs greater investment in R&D and is more complicated.
Get Free Sample:- https://wemarketresearch.com/sample-request/biosimilars-market/5/
Global Biosimilar Market: Segment Analysis
Biosimilar Market segment based on Molecule
• Filgrastim
• Rituximab
Filgrastim injection is for the treatment of Neutropenia, that is low white blood cells in the body, which is caused by cancer medicines. It is a synthetic form of substance that is produced naturally in your body known as colony stimulating factor. Filgrastim helps the bone marrow in the body to make new white blood cells itself.
Rituximab is used to treat certain types of Cancer such as Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Lukemia. It slows or stops the growth of cancer cells. Some products of Rituximab are also used to treat the pain of Rheumatoid Arthritis and can also decrease swelling and pain of the joints.
Segmentation based on Indication Insights
Oncology
Female Infertility
Oncology is the largest segment in this market due to the availability of Biosimilar at a lower price than Innovation Biologics and a large number of cancer patients. The availability of Biosimilar in Oncology has reduced the prices and made cancer treatment more accessible and affordable. Due to the high prevalence of cancer, healthcare systems across the globe are more concentrated on reducing the burden of cancer by adopting cost effective treatment options.
Biologics are too expensive and cannot be afforded by everyone. Therefore, cost-effective and new Biosimilars are being manufactured in the market. In January 2016, Teva Pharmaceutical Industries Ltd. introduced Ovaleap, a biosimilar to GONAL-f (follitropin alfa) from Merck KGaA. The low cost of Biosimilars promotes patient trust and boosts the market growth.
Segmentation based on Manufacturing
Contract Manufacturing
In- house Manufacturing
Based on the type of manufacturing, the market is classified into in-house manufacturing and contract manufacturing. Amongst these, in-house manufacturing holds the majority of the market share.
Top Key Players:-
LG Life Sciences
Fresenius SE & Co. KGaA
Pfizer, Inc.
Hospira
STADA Arzneimittel AG
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Genentech (Roche Group).
Synthon Pharmaceuticals, Inc.
Celltrion
Boehringer Ingelheim
Amgen, Inc.
Gedeon Richter PLC
Merck Serono (Merck Group)
Teva Pharmaceutical Industries Ltd.
Biocon Limited
Samsung Biologics
Biogen idec, Inc.
Coherus BioSciences
Viatris, Inc
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Interested in purchasing this Report? Click here:- https://wemarketresearch.com/purchase/biosimilars-market/5/?license=single
Frequently Asked Questions (FAQ):
What is the impact of COVID-19 on the biosimilars market?
Who are the key players in the biosimilars market?
Which product segment dominates in the biosimilars market?
Which indication segment of the global biosimilars market is expected to witness the highest growth?
What is the market size for biosimilars market?
About We Market Research
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
We Market Research
Phone: +1(929)-450-2887
Email: [email protected]
Web: https://wemarketresearch.com/
0 notes
Text
Global Bendamustine Injection Market 2021 Industry Analysis by Sales, Demand, Upcoming Trends, Consumption and Growth, Forecast 2027: Ken Research
Global Bendamustine Injection Market 2021 Industry Analysis by Sales, Demand, Upcoming Trends, Consumption and Growth, Forecast 2027: Ken Research
Bendamustine injection is utilized to cure chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Bendamustine injection is also utilized to treat a type of non-Hodgkins lymphoma (NHL: cancer that starts in a type of white blood cell that generally fights infection) that is sluggish spreading, but has persisted to worsen throughout or after treatment with another…
View On WordPress
#Bendamustine Injection Industry In Global#Bendamustine Injection Market#Bendamustine Injection Market In Global#Company Profiles of Global Bendamustine Injection Market#Covid-19 Impact Global Bendamustine Injection Industry#Covid-19 Impact Global Bendamustine Injection Market#Global Bendamustine Injection Industry#Global Bendamustine Injection Industry Research Report#Global Bendamustine Injection Market#Global Bendamustine Injection Market Analysis#Global Bendamustine Injection Market Case Study#Global Bendamustine Injection Market Competition#Global Bendamustine Injection Market Forecast#Global Bendamustine Injection Market Future Outlook#Global Bendamustine Injection Market Growth#Global Bendamustine Injection Market Growth Strategy Report#Global Bendamustine Injection Market Major Players#Global Bendamustine Injection Market Overview#Global Bendamustine Injection Market Research Report#Global Bendamustine Injection Market Revenue#Global Bendamustine Injection Market Segmentation#Global Bendamustine Injection Market Share#Global Bendamustine Injection Market Size#Global Bendamustine Injection Market Trends#Global Bendamustine Injection Market Value Chain Analysis#Global Bendamustine Injection Research Report#Growth Drivers of Global Bendamustine Injection Market#Industry Research Report Of Global Bendamustine Injection#Market Research Report Of Global Bendamustine Injection#Trends and Developments in Global Bendamustine Injection Market
0 notes
Text
Blood Cancer Drugs Market to Generate Exciting Opportunities in the Industry by 2027
The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
Request For Discount: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world
Contact us
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
Web: www.polarismarketresearch.com
0 notes
Text
Hematologic Malignancies Market Business Analysis, Share, Revenue & Sales Till 2025
23rd June 2021 – Global Hematologic Malignancies Market is predicted to reach USD 85.8 billion by 2025 depending on the growing prevalence of hematologic malignancies across the globe. Hematologic malignancies are also known as blood cancers that are found in bone marrow, blood and lymph nodes. Hematologic malignancies are the fifth most commonly globally occurring cancer and is a major reason behind cancerous death in United States. This cancer is projected to increase widely which also increases the need for its treatment. This will ultimately influence the hematologic malignancies industry in forecast period.
Hematologic malignancies initiates in the bone marrow and consequently affects the production of blood and overall functionality. The stem cells present in the bone marrow support the development of RBC (red blood cells), WBC (white blood cells) and platelets. In cases of hematological malignancies, abnormal blood cells multiply abruptly resulting in various infections such as lymphoma, leukemia and myeloma. The classification of hematologic malignancies comprises leukemia (acute lymphocytic [ALL], acute myeloid [AML], chronic myeloid [CML], chronic lymphocytic [CLL]), myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s [NHL]). Disappointingly, neither there are any defined causes of hematological malignancies, nor there are any proven methods to avoid it. On the other hand, there are various risk factors associated with these type of cancers like sickness (fever), constant headaches and fatigue.
Access Hematologic Malignancies Market Report with TOC @ https://www.millioninsights.com/industry-reports/hematologic-malignancies-market
The current generation lives a sedentary lifestyle which results in a large number disorders. Such an unhealthy lifestyle is a major factor and is predicted to accelerate the growth of hematologic malignancies market in the coming years. The increasing focus on research and development activities and modernizations in the healthcare field is estimated to boost the hematological malignancies market. Additionally, the increasing awareness among consumers regarding the availability of enhanced treatments is estimated to create promising growth opportunities for the market players in future. Conversely, the inflated cost of branded drugs and lack of reimbursement policies are likely to obstruct the growth of hematologic malignancies industry in the next few years. Also, the growing number of mergers & acquisitions are expected to fuel the growth of the market considerably in the forthcoming years.
The hematologic malignancies market is categorized on the grounds of disease condition, therapy, distribution channel and geography. On the grounds of disease condition, the market is divided into Leukemia, Lymphoma and Myeloma. On the grounds of therapy, the hematologic malignancies industry is divided into Chemotherapy, Immunotherapy and Targeted Therapy. Over the last few years, immunotherapy led the demand with a significant share in the entire market. This is due to the therapy is known to be most efficient and has lowest risk of side-effects. On the grounds of distribution channel, hematologic malignancies market is divided into Hospital Pharmacies, Medical Stores and E-commerce Platform.
Geographically, the hematologic malignancies industry is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to experience high growth in the forecast period owing to increasing patients of hematological cancers and the improved diagnostic techniques. The prominent market players profiled here include Bristol-Myers Squibb, AbbVie, Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd., Novartis AG and GlaxoSmithKline.
Request a Sample Copy of Hematologic Malignancies Market Report @ https://www.millioninsights.com/industry-reports/hematologic-malignancies-market/request-sample
0 notes
Text
Blood Cancer Drugs Market Competitive Strategies And Global Review 2017-2025
New York, NY 13 May 2021: The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
Polaris Market Research has segmented the global blood cancer drugs market on the basis of type, drugs, treatment approaches and region:
Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type
Lymphoma
Leukemia
Myeloma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
B-cell Lymphoma
T-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Burkitt Lymphoma
Central Nervous System Lymphoma
Precursor T-Lymphoblastic Lymphoma
Peripheral T-Lymphoma
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs
Rituaxan/Mabthera (Rituximab)
Gleevac/Glivec (Imatinib)
Revlimid (Lenalidomide)
Velcade (Bortezomib)
Tasigna (Nilotinib)
Pomalyst (Pomalidomide)
Vidaza (Azacitidine)
Kyprolis (Carfilzomib)
Adcetris (Brentuximab Vedotin)
Others
Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches
Chemotherapeutic
mAbs/Targeted Therapies
Immunotherapeutic
Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-customization
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: http://www.polarismarketresearch.com
0 notes
Text
Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research
Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.
According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.
Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"
https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html
The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.
Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.
Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399
Customers can also request for 10% free customization on this report.
“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.
Browse Related Reports:
Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026
https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html
Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026
https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/
For More Market Research Blogs Visit: https://techsciblog.com/
#TechSci#Market Research Reports#Healthcare#Cancer Biopsy Market#Global Cancer Biopsy Market#Cancer Biopsy Market Size#Cancer Biopsy Market Share#Cancer Biopsy Market Trend#Cancer Biopsy Market Forecast#Medical Devices
0 notes
Text
Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research
Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.
According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.
Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"
https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html
The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.
Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.
Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399
Customers can also request for 10% free customization on this report.
“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.
Browse Related Reports:
Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026
https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html
Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026
https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/
For More Market Research Blogs Visit: https://techsciblog.com/
#TechSci#Market Research Reports#Global Cancer Biopsy Market#Cancer Biopsy Market#Cancer Biopsy Market Size#Cancer Biopsy Market Share#Cancer Biopsy Market Trend#Cancer Biopsy Market Forecast#Healthcare
0 notes
Text
Blood Cancer Drugs Market Size, Share, Trends and Future Analysis by PMR
The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
Download Sample copy : https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
Have Questions? make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
0 notes
Link
Non-Hodgkin’s Lymphoma (NHL), has been expected to reach a new landscape in the forecast period due to the constant innovation and improvements on finding a viable drug to battle this disease. Due to the inability of major pharmaceuticals companies having a viable solution to it, the cost of treatment is very high and hence, the market is expected to soar higher in the forecast period of 2018-2025.
#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Industry Analysis#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market Research Report#Global Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Research Report#Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Market#Non-Hodgkin’s Lymphoma and Chronic Lymphoma Treatment Research Report
0 notes
Text
Cancer Immunotherapy Market by Leading Manufacturers According to Its Application and Types Till 2027
Cancer Immunotherapy Market: An Overview
The Global Cancer Immunotherapy Market size is forecast to surpass USD 153.03 billion in 2027 from USD 78.04 billion in 2019, delivering a CAGR of 10.1% over the forecast period. Increased cancer incidence, higher adoption of immunotherapy drugs as compared to standard treatments, increasing investments for monoclonal antibodies and biosimilars development, and more streamlined drug approval scenario, are the key factors driving global cancer immunotherapy market growth. Government and cancer research institutes are investing in research and development in various cell therapies would drive the market further. As an example , the University of Texas MD Anderson Cancer Center announced positive outcomes to its Phase 1/2a clinical trials for CAR-NK cell therapy for chronic leukemia and Hodgkin’s Lymphoma. Also, Kite, a Gilead company, announced that KTE-X19, their CAR- T therapy, has been authenticated under European Medicines Agency. However, the complicated procedures conducted in cell therapies could be time-consuming and expensive, and this would be a restraint for the market. Strict government regulations are expected to hamper the market over the forecast period.
Get a sample copy of the report @ https://www.reportsanddata.com/sample-enquiry-form/1550
Cancer Immunotherapy Market Dynamics
A paradigm shift from traditional chemotherapies to immunotherapies has created a rewarding growth scope for the cancer immunotherapy industry. Immuno-oncology has exhibited encouraging results with lower toxicity and better survival rates. Increasing effectiveness and efficacy of stem cell therapies will boost patient preference for immunotherapy. In 2018, a report estimated that the global cancer burden recorded 18.1 million new cases and 9.6 million deaths globally. The rising occurrence has prompted various government and cancer research institutes to intensify investment in research & development of varied sorts of cell therapies for the treatment of cancer. Moreover, various sorts of immunotherapies, like immunomodulators and CAR T-cell therapy, are being examined for improved outputs. The continuing research and new approvals are expected to foster cancer immunotherapy market share over the forecast period. However, immunotherapy side effects can range from mild up to life-threatening cases owing to certain circumstances of the patients’ health. Severe cases of side effects can occur when an overstimulated immune reaction is experienced. Comparatively, the traditional targeted therapy or chemotherapy can adversely attack non-cancerous cells, leading to hair loss, nausea, and a few other mild to moderate side effects. To identify the key trends within the industry, click on the link below@ https://www.reportsanddata.com/report-detail/cancer-immunotherapy-market
Cancer Immunotherapy Market: Regional Outlook North America dominated the cancer immunotherapy market with a revenue of USD 66.21 billion in 2019 and is estimated to register a rate of growth of 14.1% through 2027. The expansion is often attributed to rising technological advancements within the medical field, like the event of CRISPR for cancer treatment. The cancer immunotherapy market report in Europe estimates that the industry will exhibit a CAGR of 13% over the analysis period on account of the introduction of favorable medical reimbursement policies within the region. The cancer immunotherapy market analysis within the Asia Pacific is anticipated to witness a maximum rate of growth of 17.2% over the forecast period on account of the presence of a huge patient pool affected by various sorts of cancer in India and China. Cancer Immunotherapy Market: Key Players • Bristol-Myers Squibb • Celgene Corporation • Novartis International Ag, Amgen Inc. • Merck & Co. Inc. • Seattle Genetics Inc • Printegra, Janssen Global Services, LLC • Gristone Oncology, and Inc • Pfizer Inc.
Impact of COVID-19 on Cancer Immunotherapy Market:
After the COVID-19 outbreak, a serious concern among the medical profession was contemplating if using cancer immunotherapy in COVID-19 patients would produce to any complications or worsen their conditions. These concerns were set aside by a preliminary analysis at the University of Cincinnati Cancer Center. The initial data indicated that immunotherapy doesn't radically worsen the complications for COVID-19-positive patients with cancer. However, immunotherapy did not prove to be very effective either and therefore put aside as a possible treatment for coronavirus.
Another dramatic change within the healthcare sector occurred by popularity of digitalization. Worldwide lockdowns and therefore the general panic surrounding the rapid spread of the infection made it challenging for patients to go to hospitals, which, in many cases, were treating COVID-19 patients. Thus, to avoid going to hospitals and get access to healthcare, patients and doctors resorted to telemedicine. The crisis created by COVID-19 helped to bring light the benefits of tele-oncology and the way it can curb the fatality of cancer in rural areas where access to healthcare is limited. Cancer immunotherapy market analysis indicates that tele-oncology will open up new growth prospects for the market in the future.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1550
Report Highlights:
· Detailed overview of the market
· Evolving cancer immunotherapy market dynamics
· In-depth cancer immunotherapy market classification
· Historical, present, and anticipated cancer immunotherapy market size and share in terms of volume and value
· Recent cancer immunotherapy market trends and advances
· Competitive landscape
· Strategies adopted by key players and products portfolio
· Segments, sub-segments, and geographic regions exhibiting growth prospects
· A neutral and global perspective on cancer immunotherapy market performance
Cancer Immunotherapy Market: Segmentation
For the purpose of this report, Reports and Data has segmented into the Global Cancer Immunotherapy Market on the basis of technology, application, end use, and region:
Technology Outlook (Revenue, USD Billion; 2017-2027)
Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immune System Modulators
Adoptive Cell Transfer
Cytokines
Others
Application Outlook (Revenue, USD Billion; 2017-2027)
Head & Neck Cancer
Blood Cancers
Liver Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Melanoma
Others
End Use Outlook (Revenue, USD Billion; 2017-2027)
Cancer Research Centers
Hospitals
Clinics
Others
Regional Outlook (Revenue, USD Billion; 2017-2027)
U.S.
Germany
U.K.
France
Spain
Italy
Rest of Europe
China
India
Japan
South Korea
Rest of Asia Pacific
Brazil
Thank you for reading our report. The customization of the report is available as per your research needs. Please get in touch with us, and our team will ensure you get the report tailored as per your requirements.
Related Report:
1. Pressure Ulcers Treatment Market Size, Share & Analysis, By Material, By End-User, By Application, By Region Forecast To 2027
2. Facial Erythema Therapeutics Market Trends, Share & Size, By Product Type, By Application, By End-Use, By Region Forecast To 2027
0 notes
Text
Leukemia Therapeutics Market 2020: Company Profiles, Industry Segments, Size, Landscape, Demand and Business Trends
Market Research Future published a half-Cooked research report on “Global Leukemia Therapeutics Market Research Report, forecast to 2023” – Market Size, Share, Growth, Analysis, Regional Outlook, Scope, Stake, Progress, Trends.
Leukemia Therapeutics Market Overview
Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.
Read more news on: https://www.medgadget.com/2020/08/leukemia-therapeutics-market-to-grow-at-a-cagr-of-5-3-by-2023-covid-19-impact-analysis-top-comapnies-pfizer-inc-glaxosmithkline-plc-novartis-ag-bristol-myers-squibb-company-sanofi-s-a.html
Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).
The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.
On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.
Leukemia Therapeutics Market - Segments
The Leukemia Therapeutics Market is segmented into three main dynamics to widen the scope of understanding,
By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.
By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.
By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.
These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.
Leukemia Therapeutics Market - Regional Analysis
North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.
Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.
Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.
The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.
Leukemia Therapeutics Market - Competitive Analysis
The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.
Leukemia Therapeutics Market Major Players:
Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.
Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425
Leukemia Therapeutics Industry/ Innovation/Related News:
March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).
January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.
#Leukemia Therapeutics Market#Leukemia Therapeutics Market Size#Leukemia Therapeutics Market Share#Leukemia Therapeutics Market Growth#Leukemia Therapeutics Market Analysis#Leukemia Therapeutics Market Trends
0 notes
Text
Global Leukemia Therapeutics Market 2019 - 2023: Emerging Technologies, Business Trends, Industry Segments, Global Segments, Landscape and Demand
Global Leukemia Therapeutics Market Report, Forecast Period 2023-2020. The Industry Research Report on Global Leukemia Therapeutics Market is based on Industry Size, Share, Trend and Growth.
Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.
Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).
The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.
On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.
Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/7425
Global Leukemia Therapeutics Market - Segments
The market is segmented into three main dynamics to widen the scope of understanding,
By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.
By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.
By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.
These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.
Global Leukemia Therapeutics Market - Regional Analysis
North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.
Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.
Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.
The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.
Global Leukemia Therapeutics Market - Competitive Analysis
The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.
Major Players:
Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.
Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425
Industry/ Innovation/Related News:
March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).
January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.
0 notes
Link
The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
Request For Discount: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world
Contact us
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
Web: www.polarismarketresearch.com
0 notes
Text
Hematologic Malignancies Market Future Insights Demand, Size & Applications Forecast To 2028
San Francisco, CA - Hematologic Malignancies Market is predicted to reach USD 85.8 billion by 2025 depending on the growing prevalence of hematologic malignancies across the globe. Hematologic malignancies are also known as blood cancers that are found in bone marrow, blood and lymph nodes. Hematologic malignancies are the fifth most commonly globally occurring cancer and is a major reason behind cancerous death in United States. This cancer is projected to increase widely which also increases the need for its treatment. This will ultimately influence the hematologic malignancies industry in forecast period.
Hematologic malignancies initiates in the bone marrow and consequently affects the production of blood and overall functionality. The stem cells present in the bone marrow support the development of RBC (red blood cells), WBC (white blood cells) and platelets. In cases of hematological malignancies, abnormal blood cells multiply abruptly resulting in various infections such as lymphoma, leukemia and myeloma.
This Research will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) @ https://www.millioninsights.com/industry-reports/hematologic-malignancies-market/request-sample
The classification of hematologic malignancies comprise leukemia (acute lymphocytic [ALL], acute myeloid [AML], chronic myeloid [CML], chronic lymphocytic [CLL]), myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s [NHL]). Disappointingly, neither there are any defined causes of hematological malignancies, nor there are any proven methods to avoid it. On the other hand, there are various risk factors associated with these type of cancers like sickness (fever), constant headaches and fatigue.
The current generation lives a sedentary lifestyle which results in a large number disorders. Such an unhealthy lifestyle is a major factor and is predicted to accelerate the growth of hematologic malignancies market in the coming years. The increasing focus on research and development activities and modernizations in the healthcare field is estimated to boost the hematological malignancies market. Additionally, the increasing awareness among consumers regarding the availability of enhanced treatments is estimated to create promising growth opportunities for the market players in future. Conversely, the inflated cost of branded drugs and lack of reimbursement policies are likely to obstruct the growth of hematologic malignancies industry in the next few years. Also, the growing number of mergers & acquisitions are expected to fuel the growth of the market considerably in the forthcoming years.
The hematologic malignancies market is categorized on the grounds of disease condition, therapy, distribution channel and geography. On the grounds of disease condition, the market is divided into Leukemia, Lymphoma and Myeloma. On the grounds of therapy, the hematologic malignancies industry is divided into Chemotherapy, Immunotherapy and Targeted Therapy. Over the last few years, immunotherapy led the demand with a significant share in the entire market. This is due to the therapy is known to be most efficient and has lowest risk of side-effects. On the grounds of distribution channel, hematologic malignancies market is divided into Hospital Pharmacies, Medical Stores and E-commerce Platform.
Regional Analysis For Hematologic Malignancies Market:
For comprehensive understanding of market dynamics, the global Hematologic Malignancies Market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, Latin America and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
Significant Features that are under Offering and Key Highlights of the Reports:
Detailed overview of Hematologic Malignancies Market
Changing market dynamics of the Hematologic Malignancies industry
In-depth market segmentation by Type, Application etc
Historical, current and projected market size in terms of volume and value
Recent Hematologic Malignancies industry trends and developments
Competitive landscape of Hematologic Malignancies Market
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth.
Get Access To TOC Covering 200+ Topics @ https://www.millioninsights.com/industry-reports/hematologic-malignancies-market
0 notes